Russia
Russia

Time filter

Source Type

News Article | May 10, 2017
Site: globenewswire.com

– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019 – – Initial data from three wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) in up to eight tumor indications anticipated in 2017 and 2018 – – Updated NY-ESO data to be presented in an oral presentation at the upcoming Annual American Society of Clinical Oncology (ASCO) Meeting – PHILADELPHIA and OXFORD, U.K., May 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results and business updates for the quarter ended March 31, 2017. “Adaptimmune is now funded through to late 2019, providing us with a clear runway to deliver clinical data from multiple SPEAR T-cell therapies,” commented James Noble, Adaptimmune’s Chief Executive Officer. “We have also just initiated a study with our AFP SPEAR T-cells and expect to deliver initial data from all our wholly-owned assets in 2017 and 2018, as well as data from the NY-ESO program under option to GSK. Additionally, we will be providing an update from our NY-ESO synovial sarcoma program in an oral presentation at the upcoming ASCO annual meeting.” Financial Results for the Three Months ended March 31, 2017 Financial Guidance As of March 31, 2017, Adaptimmune had $170.6 million of cash and cash equivalents, and $33.1 million of short-term deposits representing a total liquidity position2 of $203.7 million. The Company believes that this position, combined with the net proceeds from the April 10, 2017 registered direct offering of $41.8 million, will fund the Company’s current operating plan through to late 2019. 1 Total liquidity position is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below. 2 Total liquidity position is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below. Conference Call Information The Company will host a live teleconference and webcast to provide an overview of its financial results and a business update at 8:00 a.m. EDT (1:00 p.m. BST) today, May 10, 2017. The live webcast of the conference call will be available via the events page of Adaptimmune’s corporate website at www.adaptimmune.com. An archive will be available after the call at the same address. To participate in the live conference call, if preferred, please dial (877) 280-1254 (U.S.) or +44 (0)20 3427 1911 or 0800 279 5004 (U.K.). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (4642775). About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. Total Liquidity Position (a non-GAAP financial measure) Total liquidity position (a non-GAAP financial measure) is defined as cash and cash equivalents plus short-term deposits. Each of these components appears in the Consolidated Balance Sheet. The U.S. GAAP financial measure most directly comparable to total liquidity position is cash and cash equivalents as reported in the Consolidated Financial Statements. This position is after inclusion of net proceeds from the March 2017 public offering ($61.4 million), but prior to inclusion of net proceeds from the April 2017 registered direct offering to Matrix ($41.8 million). The Company believes that the presentation of total liquidity position provides useful information to investors because management reviews total liquidity position as part of its management of overall liquidity, financial flexibility, capital structure and leverage. (1) Certain costs have been reclassified in prior periods to conform to the current period presentation.  The net effect is to reduce G&A and increase R&D by $588,000 in the three months ended March 31, 2016. (2) The effect of 67,828,170 and 44,159,031 share options, which are potentially dilutive equity instruments, have been excluded from the diluted loss per share calculation for the three months ended March 31, 2017 and 2016, respectively, because they would have an antidilutive effect on the loss per share for the period.


Browse 20 Tables and 11 Figures, 17 major company profiles, spread across 129 pages available at http://www.reportsnreports.com/reports/992869-uveal-melanoma-pipeline-review-h1-2017.html. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The Uveal Melanoma - Drug Profiles are AU-011 and BPX-701 Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma - Drug Profile: crizotinib, emibetuzumab, entinostat, entolimod, glembatumumab vedotin, hI-con1, HPH-196, HPH-211, IMCgp-100, ipilimumab + nivolumab, KCN-1, LXS-196, melphalan, merestinib, NAV-2729, nutlin-3, pasireotide ER, pegargiminase, PEP-010, sotrastaurin acetate, sunitinib malate The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. Companies Involved in Therapeutics Development are Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celldex Therapeutics Inc, Cleveland BioLabs Inc, Delcath Systems Inc, Eli Lilly and Company, Iconic Therapeutics Inc, Immunocore Ltd, Lion Biotechnologies Inc, Navigen Inc, Novartis AG, PEP-Therapy SAS, Pfizer Inc, Polaris Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Syndax Pharmaceuticals Inc. Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology) Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/. ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


PHILADELPHIA and OXFORD, U.K., May 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally advanced or metastatic hepatocellular carcinoma, the sixth most common cancer worldwide. This study is now open for enrollment. This is Adaptimmune’s second wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapy targeting the MAGE-A10 cancer antigen in patients with non-small cell lung cancer, urothelial cancer, melanoma, or head and neck cancers. “We are excited to initiate this study to evaluate our AFP T-cell therapeutic candidate in patients with hepatocellular carcinoma,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “HCC is one of the more common and deadly types of cancer worldwide and there is an urgent need for effective therapies for advanced disease.” This is a Phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity of Adaptimmune’s alpha fetoprotein (AFP) therapeutic candidate in hepatocellular carcinoma (HCC). The study will enroll up to 30 patients with measurable, histologically confirmed HCC, not amenable to resection or loco-regional therapy, and with progressive disease. The primary objective of the study is to evaluate the safety and tolerability of this second-line therapy (post-sorafenib) in patients with AFP-positive HCC. Additional objectives include anti-tumor activity, persistence of genetically modified cells in the body, and evaluation of the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion. Additional information about this study is available at www.clinicaltrials.gov by searching on NCT03132792. About Hepatocellular (Liver) Cancer A cancer that starts in the liver is called primary liver cancer. Hepatocellular carcinoma is the most common type of liver cancer in adults. Many patients who develop liver cancer have long-standing cirrhosis (scar tissue formation from liver cell damage), and early detection can be difficult because signs and symptoms often do not appear until later stages. It is estimated that approximately 40,710 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed (about 29,200 in men and 11,510 in women, and about 28,920 people will die from these cancers (about 19,610 men and 9,310 women) in the United States in 2017. About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.


PHILADELPHIA and OXFORD, U.K., May 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally advanced or metastatic hepatocellular carcinoma, the sixth most common cancer worldwide. This study is now open for enrollment. This is Adaptimmune’s second wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapy targeting the MAGE-A10 cancer antigen in patients with non-small cell lung cancer, urothelial cancer, melanoma, or head and neck cancers. “We are excited to initiate this study to evaluate our AFP T-cell therapeutic candidate in patients with hepatocellular carcinoma,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “HCC is one of the more common and deadly types of cancer worldwide and there is an urgent need for effective therapies for advanced disease.” This is a Phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity of Adaptimmune’s alpha fetoprotein (AFP) therapeutic candidate in hepatocellular carcinoma (HCC). The study will enroll up to 30 patients with measurable, histologically confirmed HCC, not amenable to resection or loco-regional therapy, and with progressive disease. The primary objective of the study is to evaluate the safety and tolerability of this second-line therapy (post-sorafenib) in patients with AFP-positive HCC. Additional objectives include anti-tumor activity, persistence of genetically modified cells in the body, and evaluation of the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion. Additional information about this study is available at www.clinicaltrials.gov by searching on NCT03132792. About Hepatocellular (Liver) Cancer A cancer that starts in the liver is called primary liver cancer. Hepatocellular carcinoma is the most common type of liver cancer in adults. Many patients who develop liver cancer have long-standing cirrhosis (scar tissue formation from liver cell damage), and early detection can be difficult because signs and symptoms often do not appear until later stages. It is estimated that approximately 40,710 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed (about 29,200 in men and 11,510 in women, and about 28,920 people will die from these cancers (about 19,610 men and 9,310 women) in the United States in 2017. About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.


PHILADELPHIA and OXFORD, U.K., May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE‑A4 SPEAR T-cell study in patients with multiple malignant solid tumors. This study is now open for enrollment. This is Adaptimmune’s third wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapies targeting the MAGE-A10 cancer antigen in patients with non-small cell lung cancer, urothelial cancer, melanoma, or head and neck cancers; and AFP in patients with hepatocellular carcinoma. “We are excited to initiate this study to evaluate our MAGE-A4 T-cell therapeutic candidate in patients with multiple malignant solid tumors,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “Preclinical evaluations of our MAGE-A4 affinity matured T-cell receptor show optimized targeting of, and specificity for, MAGE-A4 expressing cancer cells. MAGE-A4 is among the most commonly expressed cancer embryonic antigens; therefore, we have the opportunity to evaluate the potential of this promising therapy in a wide range of cancers.” This is a Phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity of Adaptimmune’s MAGE-A4 therapeutic candidate in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial, head and neck, ovarian, non-small cell lung, esophageal, and gastric cancers expressing MAGE-A4. The study will enroll up to 32 patients. The primary objective of the study is to evaluate the safety and tolerability of MAGE-A4 SPEAR T-cell therapy. Additional objectives include anti‑tumor activity, persistence of genetically modified cells in the body, and evaluation of the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion. Additional information about this study is available at www.clinicaltrials.gov by searching on NCT03132922. About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.


PHILADELPHIA and OXFORD, U.K., May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE‑A4 SPEAR T-cell study in patients with multiple malignant solid tumors. This study is now open for enrollment. This is Adaptimmune’s third wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapies targeting the MAGE-A10 cancer antigen in patients with non-small cell lung cancer, urothelial cancer, melanoma, or head and neck cancers; and AFP in patients with hepatocellular carcinoma. “We are excited to initiate this study to evaluate our MAGE-A4 T-cell therapeutic candidate in patients with multiple malignant solid tumors,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “Preclinical evaluations of our MAGE-A4 affinity matured T-cell receptor show optimized targeting of, and specificity for, MAGE-A4 expressing cancer cells. MAGE-A4 is among the most commonly expressed cancer embryonic antigens; therefore, we have the opportunity to evaluate the potential of this promising therapy in a wide range of cancers.” This is a Phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity of Adaptimmune’s MAGE-A4 therapeutic candidate in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial, head and neck, ovarian, non-small cell lung, esophageal, and gastric cancers expressing MAGE-A4. The study will enroll up to 32 patients. The primary objective of the study is to evaluate the safety and tolerability of MAGE-A4 SPEAR T-cell therapy. Additional objectives include anti‑tumor activity, persistence of genetically modified cells in the body, and evaluation of the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion. Additional information about this study is available at www.clinicaltrials.gov by searching on NCT03132922. About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.


PHILADELPHIA and OXFORD, U.K., May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE‑A4 SPEAR T-cell study in patients with multiple malignant solid tumors. This study is now open for enrollment. This is Adaptimmune’s third wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapies targeting the MAGE-A10 cancer antigen in patients with non-small cell lung cancer, urothelial cancer, melanoma, or head and neck cancers; and AFP in patients with hepatocellular carcinoma. “We are excited to initiate this study to evaluate our MAGE-A4 T-cell therapeutic candidate in patients with multiple malignant solid tumors,” said Rafael Amado, Adaptimmune’s Chief Medical Officer. “Preclinical evaluations of our MAGE-A4 affinity matured T-cell receptor show optimized targeting of, and specificity for, MAGE-A4 expressing cancer cells. MAGE-A4 is among the most commonly expressed cancer embryonic antigens; therefore, we have the opportunity to evaluate the potential of this promising therapy in a wide range of cancers.” This is a Phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity of Adaptimmune’s MAGE-A4 therapeutic candidate in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial, head and neck, ovarian, non-small cell lung, esophageal, and gastric cancers expressing MAGE-A4. The study will enroll up to 32 patients. The primary objective of the study is to evaluate the safety and tolerability of MAGE-A4 SPEAR T-cell therapy. Additional objectives include anti‑tumor activity, persistence of genetically modified cells in the body, and evaluation of the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion. Additional information about this study is available at www.clinicaltrials.gov by searching on NCT03132922. About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com Forward-Looking Statements This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.


News Article | April 21, 2017
Site: www.acnnewswire.com

Proposed Appointment of Alvin Cheng as CEO of Manager of EC World REIT EC World Asset Management Pte. Ltd., as manager of EC World Real Estate Investment Trust ("ECW") (the "Manager") is pleased to announce that it is proposing to appoint Mr. Alvin Cheng as the Executive Director and Chief Executive Officer ("CEO") of the Manager, pending approval from the Monetary Authority of Singapore. Prior to this proposed appointment, Mr. Cheng served as the Executive Director and Deputy CEO of the Manager. Mr. Lai Hock Meng will be stepping down from the CEO position to pursue personal and other business interests, but he will remain on the Board of the Manager as a Director. Said Mr. Zhang Guobiao, Chairman of the Board of the Manager, "Alvin has had a distinguished career in REIT management and corporate finance, and he brings with him deep experience and understanding of the REIT sector. We are delighted to have him leading the management team going forward." "On behalf of the Board, we will also wish to express our sincere appreciation for Mr. Lai for his commitment, valuable contributions towards the success listing of ECW last year and his leadership since the IPO." Mr. Cheng said on his proposed appointment, "during the past few months, I have got to further appreciate the potential of the ECW platform and the opportunities that lie ahead to create value for our unitholders. I am privileged to be given the opportunity to lead the Manager and I look forward to building upon the solid groundwork laid by Mr. Lai." DBS Bank Ltd. was the sole financial adviser, global coordinator and issue manager for the initial public offering of EC World REIT. DBS Bank Ltd., Bank of China Limited, Singapore Branch, China International Capital Corporation (Singapore) Pte. Limited and Maybank Kim Eng Securities Pte. Ltd. were the joint bookrunners and underwriters for the initial public offering of EC World REIT. About EC World REIT Listed on 28 July 2016, EC World REIT is the first specialized logistics and e-commerce logistics REIT listed on Singapore Exchange Securities Trading Limited ("SGX-ST"). With its initial portfolio of six quality properties located in one of the largest e-commerce clusters in the Yangtze River Delta, EC World REIT offers investors unique exposure to the logistics and e-commerce sectors in Hangzhou, the People's Republic of China ("PRC"). EC World REIT's investment strategy is to invest principally, directly or indirectly, in a diversified portfolio of income-producing real estate which is used primarily for e-commerce, supply-chain management and logistics purposes, as well as real estate-related assets, with an initial geographical focus on the PRC. For more information, please visit: http://www.ecwreit.com/ EC World REIT is managed by EC World Asset Management Pte. Ltd., which is an indirect wholly-owned subsidiary of the Sponsor - Forchn Holdings Group Co., Ltd. Established in 1992 and headquartered in Shanghai, the Sponsor is a diversified enterprise group specialising in the real estate sector, industrial sector, e-commerce, logistics and finance. For more information, please visit www.forchn.com.cn For queries, please contact: Media Citigate Dewe Rogerson, i.MAGE Pte Ltd Ms Chia Hui Kheng / Ms Deborah Lim Office hours: +65 6534 5122 After office hours: +65 9690 38 41 / +65 9639 1722 Email: / Corporate Investor Relations EC World Asset Management Pte. Ltd. Mr. Jinbo Li Tel: +65 6221 9018 Email: IMPORTANT NOTICE The value of the Units and the income derived from them may fall as well as rise. The Units are not obligations of, deposits in, or guaranteed by the Manager, DBS Trustee Limited (as trustee of EC World REIT), or any of their respective affiliates. An investment in the Units is subject to investment risks, including the possible loss of the principal amount invested. Unitholders have no right to request that the Manager redeem or purchase their Units while the Units are listed. It is intended that Unitholders may only deal in their Units through trading on the SGX-ST. Listing of the Units on the SGX-ST does not guarantee a liquid market for the Units. This announcement may contain forward-looking statements that involve assumptions, risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of EC World REIT. The forecast financial performance of EC World REIT is not guaranteed. A potential investor is cautioned not to place undue reliance on these forward-looking statements, which are based on the Manager's current view of future events.


TORONTO, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rio Silver Inc. (TSX.V:RYO) (“Rio Silver” or the “Company”) and its project partner, Magellan Gold Corporation (OTCQB:MAGE) (“Magellan”), jointly (“the Partners”) announce that they have initiated exploration work on the expanded Niñobamba Project, located 330 km southeast of Lima in the Department of Ayacucho, Peru. Recent strategic additions to the land package have created a large, contiguous property consisting of 3100 hectares and another 553 hectare concessions pending title confirmation. (See news releases of September 8, 2016 and January 10, 2017). Magellan will be spending US$2 million at the Niñobamba project to earn its 50% interest. Project History: Significant historical exploration work has been conducted at several of the Niñobamba concessions over many years by previous property owners; AngloGold, Bear Creek Mining, Newmont Gold and Southern Peru Copper Corp. This historical work provides the project with much exploration data and numerous gold, silver and combined silver/gold targets in an historic silver mining district with positive infrastructure in mining-friendly Peru. A geologic environment that suggests the potential for high sulphidation, epithermal precious metal deposits has the Company’s geologists focusing first on the area trenched earlier by the Company. Two subparallel zones of silver/gold and silver mineralization; the “Niñobamba North Zone” and the “Niñobamba South Zone,” exhibited good continuity, substantial widths at surface and strike extents of 400+ meters as outlined by the results of the 17 trenches completed in the 2012 program. Mineralization demonstrates the potential for an outcropping, bulk-tonnage, and disseminated-silver/gold resource. Surface trenches were cut perpendicular to the mineralized zones and highlights of the trench assay results from the “Niñobamba North Zone” include; 56 metres of 1.03 g/t Au and 98.9 g/t silver in trench TR-01; 21 metres of 121 g/t Ag in trench TR-04; and 108 metres of 62.4 g/t Ag in trench TR-05. Highlights of the trench assay results from the “Niñobamba South Zone” include; 42 metres of 131 g/t Ag in trench TR-02; 29 metres of 119.3 g/t Ag in TR-03; and 23 metres of 92.1 g/t Ag in TR-11. All trench samples were rock saw cut channel samples and are summarized in the Company’s news release dated January 14, 2013 and are posted at the Company’s website. 2017 Program: With the recent property additions, there are potential strike extensions to the southwest of the Niñobamba North and South Zones. Additionally, there are new targets to the west on the newly added concessions that were the focus of previous gold exploration programs by Newmont Gold and Southern Peru Copper Corp. The Partners have initiated a compilation of the available new data. The review of this new data will help guide exploration that is additional to the further definition of the Niñobamba North and South Zones that will be the target of diamond drilling during the 2017 year as part of the requirements of the Magellan option to earn its property interest. The extent and timing of the 2017 exploration program will be determined shortly once all compilation materials have been reviewed by the Technical Committee that has been established by the Partners. Rio Silver’s Executive Co-Chairman, Steve Brunelle states, “The drilling of the Niñobamba Zones will be a very exciting part of our 2017 exploration effort. We anticipate a progressive outlining of a silver/gold resource at these targets. Additionally, we now possess a significant surrounding property portfolio with several intriguing gold targets to build upon. This year should be very positive for the Partners and all our shareholders.” Magellan has established its Peruvian subsidiary, and as Operator of the program, will rely upon the 20+ years of Peruvian exploration experience of the Rio Silver geological team. Magellan’s President, Pierce Carson states, “We are excited by the high quality of the exploration targets being generated, which include potentially bulk-minable disseminated precious metals as well as high grade veins. With our expanded ground position and multitude of untested or only partially tested precious metals anomalies, we believe chances are excellent for discovery of one or more economic ore deposits.”                                                            Jeffrey Reeder, P.Geo., and a qualified person as defined in National Instrument 43-101, has prepared, supervised the preparation, or approved the scientific and technical disclosure contained in this news release. ON BEHALF OF THE BOARD OF DIRECTORS OF RIO SILVER INC. Steve Brunelle Executive Co-Chairman Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required by applicable laws.


Ntegrator Secures Two Contracts Worth S$47.8 Million from a Regional Service Provider and a Singapore-Based Customer Both contracts awarded are for the supply of fibre installation and maintenance services Ntegrator International Ltd ("Ntegrator" or "the Group"), a leading regional communications network specialist and systems integrator, today announced that it has secured two major contracts worth S$47.8 million. The contracts involve the supply of fibre installation and maintenance services, and were awarded by a regional service provider and another customer. The contracts are scheduled to commence in March 2017, and cover a contract period of two years and three years respectively. The contracts are expected to contribute positively to the Group's financial performance over the next two to three financial years, subject to timely completion of the project and effective cost management. Mr. Jimmy Chang, Managing Director of Ntegrator, said, "The Group is heartened to start the year on a strong footing with these contract wins. The latest contracts awarded by two of our repeat customers in the network and communications space, underscore the Group's established track record and our strong relationships with key industry players in Singapore. The confidence placed in us by our repeat customers reinforces the Group's unrelenting commitment in delivering quality products and services. Moving forward, we will continue to leverage on the developments within the industry to capture growth opportunities in our core markets of Singapore, Vietnam and Myanmar." About Ntegrator International Ltd Established in April 2002 and listed on Catalist (formerly known as SESDAQ) three years later, on October 26, 2005, Ntegrator's core businesses include the design, installation and implementation of data, video, fibre optics, wireless and cellular network infrastructure as well as voice communication systems. The Group provides project management services as well as maintenance and support services. Headquartered in Singapore, Ntegrator has operations in the region, covering Singapore, Vietnam and Myanmar. www.ntegrator.com Issued on Behalf of Ntegrator International Ltd By Citigate Dewe Rogerson, i.MAGE Pte Ltd 55 Market Street #02-01 Singapore 048941 Contact: Mr Winston Choo / Ms Lynette Tan at telephone DURING OFFICE HOURS: +65-6534-5122 (Office) AFTER OFFICE HOURS: +65-9068-2099 / +65-9689-2846 (Handphone) EMAIL: /

Loading OAO MAGE collaborators
Loading OAO MAGE collaborators